Clinical Scorecard: Evaluating the Efficacy of 18F-DCFPyL PET/CT for Prostate Cancer Detection Against Final Histopathological Results from Radical Prostatectomy: Assessing the Viability of PSMA-Targeted Biopsy in the DeTeCT Study

At a Glance

Key Highlights

• 18F-DCFPyL PET/CT demonstrates high detection rates (98–100%) for primary prostate tumors correlating with histopathology.
• PSMA-PET/CT enables precise localization of prostate cancer lesions within a 12-segment prostate mapping model for targeted biopsy guidance.
• The imaging modality also allows assessment of local tumor staging including extracapsular extension and seminal vesicle invasion.

Guideline-Based Recommendations

Diagnosis

• Use 18F-DCFPyL PET/CT to localize primary prostate cancer lesions prior to radical prostatectomy.
• Interpret PET/CT scans using a 5-point PSMA-RADS scale; consider scores 4–5 as suspicious for prostate cancer.
• Combine PET/CT findings with clinical parameters and histopathology for comprehensive tumor assessment.

Management

• Select up to two prostate segments with highest SUVmax on PET/CT for targeted biopsy to improve diagnostic accuracy.
• Consider PSMA-PET/CT for simultaneous screening of bone and lymph-node metastases during initial staging.

Monitoring & Follow-up

• Use PET/CT imaging findings to assess local tumor stage (rT-stage) including extracapsular extension (rT3a) and seminal vesicle invasion (rT3b).

Risks

• Sampling errors and false negatives may occur with conventional systematic biopsies; PSMA-PET/CT aims to reduce these risks.
• Interpretation requires experienced nuclear medicine physicians to minimize diagnostic uncertainty.

Patient & Prescribing Data

Men with intermediate or high-risk primary prostate cancer scheduled for radical prostatectomy

18F-DCFPyL PET/CT imaging performed approximately 5 weeks prior to surgery with median radiotracer dose of 313 MBq and image acquisition around 2 hours post-injection.

Clinical Best Practices

• Perform 18F-DCFPyL PET/CT imaging using standardized protocols including BLOB-based Ordered-Subsets Expectation Maximization reconstruction.
• Interpret images blinded to histopathology and other imaging to reduce bias.
• Use a 12-segment prostate mapping model for precise lesion localization and biopsy targeting.
• Apply PSMA-RADS classification to standardize reporting and diagnostic confidence.
• Ensure multidisciplinary collaboration between nuclear medicine physicians, urologists, and pathologists for optimal patient management.

References

• European Association of Urology Guidelines on Prostate Cancer
• Jansen et al. on 18F-DCFPyL synthesis and imaging protocols
• PSMA-RADS Classification System